Publications

Mark Schurdak, PhD

Ngo M, Wechter N, Tsai E, Shun TY, Gough A, Schurdak ME, Schwacha A, Vogt A. A High-Throughput Assay for DNA Replication Inhibitors Based upon Multivariate Analysis of Yeast Growth Kinetics. SLAS Discov. 2019 Jul;24(6):669-681. doi: 10.1177/2472555219829740. PubMed PMID: 30802412; PMCID: PMC6586513.
Schurdak ME, Pei F, Lezon TR, Carlisle D, Friedlander R, Taylor DL, Stern AM. A Quantitative Systems Pharmacology Approach to Infer Pathways Involved in Complex Disease Phenotypes. Methods Mol Biol. 2018;1787207-222. doi: 10.1007/978-1-4939-7847-2_16. PubMed PMID: 29736721.
Gough A, Shun TY, Taylor DL, Schurdak M. Integrating Analysis of Cellular Heterogeneity in High-Content Dose-Response Studies. Methods Mol Biol. 2018;174525-46. doi: 10.1007/978-1-4939-7680-5_2. PubMed PMID: 29476461.
D'Aiuto L, Williamson K, Dimitrion P, McNulty J, Brown CE, Dokuburra CB, Nielsen AJ, Lin WJ, Piazza P, Schurdak ME, Wood J, Yolken RH, Kinchington PR, Bloom DC, Nimgaonkar VL. Comparison of three cell-based drug screening platforms for HSV-1 infection. Antiviral Res. 2017 Jun;142136-140. doi: 10.1016/j.antiviral.2017.03.016. PubMed PMID: 28342892; PMCID: PMC5525147.
Gough A, Stern AM, Maier J, Lezon T, Shun TY, Chennubhotla C, Schurdak ME, Haney SA, Taylor DL. Biologically Relevant Heterogeneity: Metrics and Practical Insights. SLAS Discov. 2017 Mar;22(3):213-237. doi: 10.1177/2472555216682725. PubMed PMID: 28231035; PMCID: PMC5464733.
LaPorte MG, Wang Z, Colombo R, Garzan A, Peshkov VA, Liang M, Johnston PA, Schurdak ME, Sen M, Camarco DP, Hua Y, Pollock NI, Lazo JS, Grandis JR, Wipf P, Huryn DM. Optimization of pyrazole-containing 1,2,4-triazolo-[3,4-b]thiadiazines, a new class of STAT3 pathway inhibitors. Bioorg Med Chem Lett. 2016 Aug 1;26(15):3581-5. doi: 10.1016/j.bmcl.2016.06.017. PubMed PMID: 27381083; PMCID: PMC4964800.
Gearhart TL, Montelaro RC, Schurdak ME, Pilcher CD, Rinaldo CR, Kodadek T, Park Y, Islam K, Yurko R, Marques ET Jr, Burke DS. Selection of a potential diagnostic biomarker for HIV infection from a random library of non-biological synthetic peptoid oligomers. J Immunol Methods. 2016 Aug;43585-9. doi: 10.1016/j.jim.2016.05.001. PubMed PMID: 27182050; PMCID: PMC4947968.
Stern AM, Schurdak ME, Bahar I, Berg JM, Taylor DL. A Perspective on Implementing a Quantitative Systems Pharmacology Platform for Drug Discovery and the Advancement of Personalized Medicine. J Biomol Screen. 2016 Jul;21(6):521-34. doi: 10.1177/1087057116635818. PubMed PMID: 26962875; PMCID: PMC4917453.
Delgado E, Boisen MM, Laskey R, Chen R, Song C, Sallit J, Yochum ZA, Andersen CL, Sikora MJ, Wagner J, Safe S, Elishaev E, Lee A, Edwards RP, Haluska P, Tseng G, Schurdak M, Oesterreich S. High expression of orphan nuclear receptor NR4A1 in a subset of ovarian tumors with worse outcome. Gynecol Oncol. 2016 May;141(2):348-356. doi: 10.1016/j.ygyno.2016.02.030. PubMed PMID: 26946093; PMCID: PMC5154956.
Gough A, Shun TY, Lansing Taylor D, Schurdak M. A metric and workflow for quality control in the analysis of heterogeneity in phenotypic profiles and screens. Methods. 2016 Mar 1;9612-26. doi: 10.1016/j.ymeth.2015.10.007. PubMed PMID: 26476369; PMCID: PMC5200891.
Warita K, Warita T, Beckwitt CH, Schurdak ME, Vazquez A, Wells A, Oltvai ZN. Statin-induced mevalonate pathway inhibition attenuates the growth of mesenchymal-like cancer cells that lack functional E-cadherin mediated cell cohesion. Sci Rep. 2014 Dec 23;47593. doi: 10.1038/srep07593. PubMed PMID: 25534349; PMCID: PMC4274516.
Gough AH, Chen N, Shun TY, Lezon TR, Boltz RC, Reese CE, Wagner J, Vernetti LA, Grandis JR, Lee AV, Stern AM, Schurdak ME, Taylor DL. Identifying and quantifying heterogeneity in high content analysis: application of heterogeneity indices to drug discovery. PLoS One. 2014;9(7):e102678. doi: 10.1371/journal.pone.0102678. PubMed PMID: 25036749; PMCID: PMC4103836.

<< Investigators Search

Top